A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances
Authors
Keywords
-
Journal
PHARMACOGENOMICS JOURNAL
Volume 15, Issue 2, Pages 172-176
Publisher
Springer Nature
Online
2014-08-12
DOI
10.1038/tpj.2014.42
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of cytochrome P450 genes on suicide attempt and risk
- (2013) Eva M. Peñas-Lledó et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene
- (2013) A Persson et al. MOLECULAR PSYCHIATRY
- The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder
- (2012) Peter Höfer et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Suicidal phenotypes associated with family history of suicidal behavior and early traumatic experiences
- (2012) J. Lopez-Castroman et al. JOURNAL OF AFFECTIVE DISORDERS
- Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function
- (2012) J C Stingl et al. MOLECULAR PSYCHIATRY
- CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients
- (2012) E M Peñas-LLedó et al. MOLECULAR PSYCHIATRY
- Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects
- (2012) S C Sim et al. PHARMACOGENOMICS JOURNAL
- Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping ofCYP2C9,CYP2C19andCYP2D6genes
- (2011) David Villagra et al. Biomarkers in Medicine
- CYP2D6 in the Brain: Impact on Suicidality
- (2011) J C Stingl (formerly Kirchheiner) et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP
- (2011) Patricia Huezo-Diaz et al. JOURNAL OF PSYCHOPHARMACOLOGY
- High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders
- (2011) E M Peñas-Lledó et al. MOLECULAR PSYCHIATRY
- CYP2D6and the severity of suicide attempts
- (2011) Eva M Peñas-Lledó et al. PHARMACOGENOMICS
- Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations
- (2010) Rasmus S. Pedersen et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Cytochrome P450 2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine
- (2010) Kasia W. Lobello et al. JOURNAL OF CLINICAL PSYCHIATRY
- CYP2C19 variation and citalopram response
- (2010) David A. Mrazek et al. Pharmacogenetics and Genomics
- Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response
- (2010) Ming-Hsien Tsai et al. PHARMACOGENOMICS
- Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients
- (2010) A de Vos et al. PHARMACOGENOMICS JOURNAL
- CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
- (2010) A LLerena et al. PHARMACOGENOMICS JOURNAL
- High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases
- (2009) A L Zackrisson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients
- (2009) Alessandro Serretti et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients
- (2009) P W Schenk et al. PHARMACOGENOMICS JOURNAL
- The Impact of CYP2D6 and CYP2C19 Polymorphisms on Suicidal Behavior and Substance Abuse Disorder Among Patients With Schizophrenia: A Retrospective Study
- (2009) Camilla J Kobylecki et al. THERAPEUTIC DRUG MONITORING
- Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients
- (2008) I. Rudberg et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
- (2008) Adrián LLerena et al. PHARMACOGENOMICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started